Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma
Brief Summary: Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them.

Having completed Phase 1 and Phase 2 clinical trials, Provenge is now at the Phase 3 level. One important Phase 3 trial of Provenge has been completed; the current trial is also a Phase 3 study.

If you decide to participate and are eligible, you will be enrolled in the study and randomly assigned to receive either active product or placebo. There are two chances in three that you will receive Provenge. After receiving treatment, you will be monitored at regular intervals until the study endpoints are met. At the end of the trial, men who received placebo will have the opportunity to be treated with active product in another study.


Options:
A: Arm Label: APC-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: APC-Placebo | Arm Label: Sipuleucel-T; Type: ACTIVE_COMPARATOR; Interventions: Biological: Sipuleucel-T | Intervention Type: BIOLOGICAL; Name: Sipuleucel-T; Assigned to Arm(s): Sipuleucel-T | Intervention Type: BIOLOGICAL; Name: APC-Placebo; Assigned to Arm(s): APC-Placebo
B: Arm Label: Radical prostatectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radical prostatectomy | Arm Label: Conformal radiation therapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conformal radiation therapy | Arm Label: Active monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Active monitoring | Intervention Type: PROCEDURE; Name: Radical prostatectomy; Assigned to Arm(s): Radical prostatectomy | Intervention Type: RADIATION; Name: Conformal radiation therapy; Assigned to Arm(s): Conformal radiation therapy | Intervention Type: OTHER; Name: Active monitoring; Assigned to Arm(s): Active monitoring
C: Arm Label: Arm A: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADT | Arm Label: Arm B: Zoledronic Acid; Type: EXPERIMENTAL; Interventions: Drug: ADT, Drug: Zoledronic Acid | Arm Label: Arm C: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Prednisolone, Drug: ADT | Arm Label: Arm D: Celecoxib; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib, Drug: ADT | Arm Label: Arm E: Zoledronic Acid & Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Prednisolone, Drug: ADT, Drug: Zoledronic Acid | Arm Label: Arm F: Zoledronic Acid & Celecoxib; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib, Drug: ADT, Drug: Zoledronic Acid | Arm Label: Arm G: Abiraterone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: ADT, Drug: Abiraterone | Arm Label: Arm H: M1 RT; Type: EXPERIMENTAL; Interventions: Drug: ADT, Radiation: Radiotherapy to the prostate | Arm Label: Arm J: Abiraterone * Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: ADT, Drug: Abiraterone, Drug: Enzalutamide | Arm Label: Arm K: Metformin; Type: EXPERIMENTAL; Interventions: Drug: ADT, Drug: Metformin | Arm Label: Arm L: tE2; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Oestradiol | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): Arm D: Celecoxib, Arm F: Zoledronic Acid & Celecoxib | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm C: Docetaxel, Arm E: Zoledronic Acid & Docetaxel | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Arm C: Docetaxel, Arm E: Zoledronic Acid & Docetaxel, Arm G: Abiraterone, Arm J: Abiraterone * Enzalutamide | Intervention Type: DRUG; Name: ADT; Assigned to Arm(s): Arm A: Standard of Care, Arm B: Zoledronic Acid, Arm C: Docetaxel, Arm D: Celecoxib, Arm E: Zoledronic Acid & Docetaxel, Arm F: Zoledronic Acid & Celecoxib, Arm G: Abiraterone, Arm H: M1 RT, Arm J: Abiraterone * Enzalutamide, Arm K: Metformin | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Arm B: Zoledronic Acid, Arm E: Zoledronic Acid & Docetaxel, Arm F: Zoledronic Acid & Celecoxib | Intervention Type: DRUG; Name: Abiraterone; Assigned to Arm(s): Arm G: Abiraterone, Arm J: Abiraterone * Enzalutamide | Intervention Type: RADIATION; Name: Radiotherapy to the prostate; Assigned to Arm(s): Arm H: M1 RT | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Arm J: Abiraterone * Enzalutamide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Arm K: Metformin | Intervention Type: DRUG; Name: Transdermal Oestradiol; Assigned to Arm(s): Arm L: tE2
D: Arm Label: Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Enzalutamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Enzalutamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A